FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012856564> ?p ?o ?g. }

• W2012856564 endingPage "569" @default.
• W2012856564 startingPage "561" @default.
• W2012856564 abstract "Abstract We conducted a phase I-II clinical trial to assess the safety and efficacy of combining lutetium-177 ((177)Lu)-octreotate with capecitabine and temozolomide in treating advanced low-grade neuroendocrine tumors (NETs). All 35 patients received fixed activities of 7.8 GBq (177)Lu-octreotate each 8 weeks, with 14 days of capecitabine 1500 mg/m(2) for 4 cycles. In phase I, successive cohorts of patients received escalating doses of temozolomide in groupings of 100, 150, and 200 mg/m(2) in the last 5 days of each capecitabine cycle. In phase II, patients were treated with 200 mg/m(2) temozolomide. Treatment was well tolerated in all dosage groups. No dose-limiting grade 2, 3, or 4 toxicities were seen in cohorts 1 (100 mg/m(2)) or 2 (150 mg/m(2)). Twenty-eight patients completed treatment at the 200 mg/m(2) temozolomide level. Adverse events were mild to moderate. The commonest toxicities were transient nausea grade 2 (18%), grade 3 (3%), thrombocytopenia grade 2 (24%), and neutropenia grade 3 (6%). There were no grade 4 events. Thirty-four patients were evaluable for tumor response. Overall, complete response (CR) was achieved in 15% (95% CI 3-27); partial response (PR), in 38% (95% CI 22-55); stable disease (SD), in 38% (95% CI 22-55); and 3 patients failed to respond to treatment. Median progression free survival (PFS) was 31 months (95% CI 21-33), and median overall survival (OS) has not been reached with 90% surviving at 24 months follow-up (range 21-30). Overall objective response rate (ORR) in patients with gastroenteropancreatic NETs showed CR 16% (95% CI 3-28), PR 41% (95% CI 24-58), SD 37% (95% CI 21-54), and PD 6% (95% CI 0-15). Response rates were higher in patients with gastropancreatic NETs than in those with bowel primaries (enteric-NETs); CR 18% versus 13%, PR 64% versus 13%, SD 12% versus 67%. (177)Lu-octreotate, in combination with capecitabine and temozolomide, is well tolerated in patients with advanced low-grade NETs, and shows substantial tumor control rates." @default.
• W2012856564 created "2016-06-24" @default.
• W2012856564 creator A5050960969 @default.
• W2012856564 creator A5066660671 @default.
• W2012856564 creator A5084430369 @default.
• W2012856564 date "2012-11-01" @default.
• W2012856564 modified "2023-10-04" @default.
• W2012856564 title "Phase I-II Study of Radiopeptide¹⁷⁷Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors" @default.
• W2012856564 cites W1988986189 @default.
• W2012856564 cites W2005674134 @default.
• W2012856564 cites W2019607817 @default.
• W2012856564 cites W2055850373 @default.
• W2012856564 cites W2058491998 @default.
• W2012856564 cites W2064560087 @default.
• W2012856564 cites W2065832118 @default.
• W2012856564 cites W2067351259 @default.
• W2012856564 cites W2086608867 @default.
• W2012856564 cites W2090232354 @default.
• W2012856564 cites W2096521106 @default.
• W2012856564 cites W2099933501 @default.
• W2012856564 cites W2115686439 @default.
• W2012856564 cites W2118672029 @default.
• W2012856564 cites W2125398839 @default.
• W2012856564 cites W2126251787 @default.
• W2012856564 cites W2130735070 @default.
• W2012856564 cites W2135657152 @default.
• W2012856564 cites W2137142564 @default.
• W2012856564 cites W2146272590 @default.
• W2012856564 cites W2148933046 @default.
• W2012856564 cites W2149214723 @default.
• W2012856564 cites W2158474413 @default.
• W2012856564 cites W2167834420 @default.
• W2012856564 cites W2175100454 @default.
• W2012856564 cites W2340889909 @default.
• W2012856564 cites W4243639737 @default.
• W2012856564 doi "https://doi.org/10.1089/cbr.2012.1276" @default.
• W2012856564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23078020" @default.
• W2012856564 hasPublicationYear "2012" @default.
• W2012856564 type Work @default.
• W2012856564 sameAs 2012856564 @default.
• W2012856564 citedByCount "136" @default.
• W2012856564 countsByYear W20128565642013 @default.
• W2012856564 countsByYear W20128565642014 @default.
• W2012856564 countsByYear W20128565642015 @default.
• W2012856564 countsByYear W20128565642016 @default.
• W2012856564 countsByYear W20128565642017 @default.
• W2012856564 countsByYear W20128565642018 @default.
• W2012856564 countsByYear W20128565642019 @default.
• W2012856564 countsByYear W20128565642020 @default.
• W2012856564 countsByYear W20128565642021 @default.
• W2012856564 countsByYear W20128565642022 @default.
• W2012856564 countsByYear W20128565642023 @default.
• W2012856564 crossrefType "journal-article" @default.
• W2012856564 hasAuthorship W2012856564A5050960969 @default.
• W2012856564 hasAuthorship W2012856564A5066660671 @default.
• W2012856564 hasAuthorship W2012856564A5084430369 @default.
• W2012856564 hasConcept C121608353 @default.
• W2012856564 hasConcept C126322002 @default.
• W2012856564 hasConcept C197934379 @default.
• W2012856564 hasConcept C2776694085 @default.
• W2012856564 hasConcept C2777063308 @default.
• W2012856564 hasConcept C2777389519 @default.
• W2012856564 hasConcept C2777909004 @default.
• W2012856564 hasConcept C2778375690 @default.
• W2012856564 hasConcept C2778822529 @default.
• W2012856564 hasConcept C2779066768 @default.
• W2012856564 hasConcept C2780580376 @default.
• W2012856564 hasConcept C2989005 @default.
• W2012856564 hasConcept C31760486 @default.
• W2012856564 hasConcept C526805850 @default.
• W2012856564 hasConcept C71924100 @default.
• W2012856564 hasConcept C90924648 @default.
• W2012856564 hasConceptScore W2012856564C121608353 @default.
• W2012856564 hasConceptScore W2012856564C126322002 @default.
• W2012856564 hasConceptScore W2012856564C197934379 @default.
• W2012856564 hasConceptScore W2012856564C2776694085 @default.
• W2012856564 hasConceptScore W2012856564C2777063308 @default.
• W2012856564 hasConceptScore W2012856564C2777389519 @default.
• W2012856564 hasConceptScore W2012856564C2777909004 @default.
• W2012856564 hasConceptScore W2012856564C2778375690 @default.
• W2012856564 hasConceptScore W2012856564C2778822529 @default.
• W2012856564 hasConceptScore W2012856564C2779066768 @default.
• W2012856564 hasConceptScore W2012856564C2780580376 @default.
• W2012856564 hasConceptScore W2012856564C2989005 @default.
• W2012856564 hasConceptScore W2012856564C31760486 @default.
• W2012856564 hasConceptScore W2012856564C526805850 @default.
• W2012856564 hasConceptScore W2012856564C71924100 @default.
• W2012856564 hasConceptScore W2012856564C90924648 @default.
• W2012856564 hasIssue "9" @default.
• W2012856564 hasLocation W20128565641 @default.
• W2012856564 hasLocation W20128565642 @default.
• W2012856564 hasOpenAccess W2012856564 @default.
• W2012856564 hasPrimaryLocation W20128565641 @default.
• W2012856564 hasRelatedWork W2007304396 @default.
• W2012856564 hasRelatedWork W2012856564 @default.
• W2012856564 hasRelatedWork W2162934203 @default.
• W2012856564 hasRelatedWork W2231709888 @default.
• W2012856564 hasRelatedWork W2287859647 @default.

• next